Rare Disease Report

Myeloproliferative Neoplasms

Interferon‐α2 and ruxolitinib combination therapy shows promise in treating myeloproliferative neoplasms, according to recent preliminary findings.
Investigators have found that the higher the symptom burden, the greater the detrimental impact on work productivity and daily activity for patients with myeloproliferative neoplasms.
Investigators in Cincinnati have linked a gene with myelodysplastic syndromes, potentially offering the first step toward a new genetic therapy.
Pauline Funchain MD, explains how better understanding of genetics can help shape future treatments for rare cancers.
Relatives of individuals with certain types of blood cancer may harbor inherited genetic changes that could influence their risk of developing diseases that arise from myeloid cells.
Investigators find boys treated with alkylating agents or with hydroxyurea for sickle cell disease resulted in a significant reduction in spermatogonial cell counts, suggesting that these agents can affect fertility.
Dr. Eric Padrone, a hematologist from H. Lee Moffit Cancer Center, discusses current thinking on MDS/MPN overlap disorders and myelofibrosis. 
Study performed by researchers at Juntendo University reveals molecular mechanisms that trigger CALR-mutant myeloproliferative neoplasms (MPNs). 
Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.
Researchers find that JAK inhibitors used to treat myelofibrosis may actually lead to the development of aggressive lymphomas.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.